Clarity Pharmaceuticals

Clarity strengthens Cu-64 network with new supply agreement with SpectronRx to ensure seamless supply of the diagnostic isotope for Clarity’s products which continue to progress through clinical trials, including a pivotal Phase III clinical trial in prostate cancer. Click here to read more: https://lnkd.in/gS2xz9Un #diagnostics #radiopharmaceuticals

There has been a lot of interest around radioisotopes in radiopharmaceuticals. But what is just hype and what will bring real hope to patients? Watch season 2 episode 3 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn about the different radioisotopes, their pros and cons, recent acquisitions in the space and the future of radiopharm.   #podcast #biotech #radiopharmaceuticals

As big pharma companies are rushing to get their toes in the waters of the radiopharmaceutical field, the sector is as hot as ever. With accelerated M&A activity in this space, Clarity continues to focus on strengthening three key pillars that differentiate it from the myriad of others: best-in-class product pipeline with excellent safety and efficacy data to date, strong intellectual property, and seamless supply & manufacturing. Watch season 2 episode 2 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn more about the radiopharmaceutical field and Clarity's competitive advantages in the space #podcast #biotech #radiopharmaceuticals

The Science Hat, a podcast series about science and innovation in the radiopharmaceutical space, is back for season 2.   Watch episode 1 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn more about Clarity Pharmaceuticals' most recent capital raise and where it places the company in the current biotech market. #TCT #biotech #radiopharmaceuticals

New data, covering Clarity's clinical results and trials in progress, will be presented at the upcoming world leading conferences, American Urological Association, American Society of Clinical Oncology (ASCO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meetings. The data showcases the extensive scope of Clarity’s Targeted Copper Theranostic platform in developing products for imaging and treating cancer patients. #TCT #prostatecancer #PSMA #SNMMI2024 #AUA24 #ASCO24

Clarity's CLARIFY Phase III study was selected for an oral presentation at the American Urological Association (AUA) annual meeting in San Antonio on Sunday May 5th during a new program titled "Clinical Trials in Progress". The presentation, titled "CLARIFY: Positron Emission Tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy, a Phase 3 diagnostic study" is scheduled for 1:45-2PM.

Click below to learn more about the exciting milestones we achieved at the start of this year as we continue to move closer to our ultimate goal of improving treatment outcomes for children and adults with cancer. #CU6 #TCT #radiopharmaceuticals #biotech

A complete response has been achieved in the first patient ever to be dosed with two cycles of 67Cu-SAR-bisPSMA at 8GBq and their PSA remains undetectable. The safety profile of 67Cu-SAR-bisPSMA appears to be favourable with few side effects observed following treatment. #prostatecancer #radiopharmaceuticals #TCT #PSMA

At Clarity, we are incredibly excited about our products advancing through clinical trials towards our ultimate goal of better treating children and adults with cancer. We pride ourselves in working with the world’s best clinicians and institutions, who share our goal of bringing valuable new treatments to their patients through clinical trials, one of which being the Mayo Clinic’s Comprehensive Cancer Center. Dr Geoff Johnson, MD, PhD is the Principal Investigator of the SECuRE theranostic trial investigating 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for detecting and treating patients with metastatic castrate-resistant prostate cancer.

Meet Clarity at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California, April 5-10. Clarity will be presenting two posters, 6037 and 6038, on the development of its Targeted Copper Theranostics on April 9 during the 13:30-17:00 session titled "Radiation, Theranostics, Radiotheranostics, Normal Tissue, and Cellular Stress".   For more information, visit the event website: https://lnkd.in/g6P3g2CD